<DOC>
	<DOCNO>NCT02078674</DOCNO>
	<brief_summary>This randomize , observer-blinded , placebo-controlled trial adult 18 64 year old . Randomization stratify age ( 18 49 year 50 64 year ) prior influenza immunization within past three month . Subjects 18 49 year age comprise ~67 % subject treatment group , balance comprise subject 50 64 year . Each subject receive two identical IM dose test article 21-day interval ( Day 0 Day 21 ) , alternate deltoid . For subject , study follow-up span approximately 385 day total , approximately 13 month first dose .</brief_summary>
	<brief_title>A ( H7N9 ) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<criteria>1 . Healthy adult male female , 18 64 year age , 2 . Willing able give inform consent prior study enrollment , 3 . Able comply study requirement , 4 . Women childbearing potential must negative urine pregnancy test prior vaccination , advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history continuous abstinence heterosexual activity prior surgical sterilization , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , barrier contraceptive ( condom diaphragm ) , intrauterine device ( IUD ) . Women adequately document history surgical sterility , ≥50 year age without menses ≥1 year exempt urine pregnancy test . Subjects exclude meet follow criterion : 1 . Any ongoing , symptomatic acute chronic illness require medical surgical care . Asymptomatic condition finding ( e.g. , mild hypertension , dyslipidemia ) associate evidence endorgan damage exclusionary provide appropriately manage clinically stable ( i.e. , unlikely result symptomatic illness within timecourse study ) opinion Investigator . Acute chronic illness condition may reasonably predict become symptomatic treatment withdrawn interrupt exclusionary , even stable . Note illness condition may exclusionary , even otherwise stable clinically minor , due therapy use treat ( see exclusion criterion 3 , 5 , 8 , 9 ) . 2 . Any grade 1 high ( base Toxicity Grading Scale [ TGS ] ) abnormality ALT , AST , alkaline phosphatase , total bilirubin , blood urea nitrogen , creatinine level . 3 . Any grade 2 high ( base TGS ) vital sign clinical laboratory abnormality specify criterion 2 . Note abnormal vital sign may repeat Investigator 's discretion . 4 . Participation research involve investigational product ( drug / biologic / device ) within 45 day plan date first vaccination . 5 . History serious reaction prior influenza vaccination . 6 . History GuillainBarré Syndrome ( GBS ) within 6 week follow previous influenza vaccine . 7 . Received vaccine 4 week precede study vaccination ; A ( H7N9 ) avian influenza vaccine time . 8 . Any known suspected immunosuppressive condition , acquire congenital , determined history and/or physical examination . 9 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 10 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 11 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration ) . 12 . Known disturbance coagulation . 13 . Women pregnant breastfeeding , plan become pregnant study . 14 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>H7N9</keyword>
</DOC>